echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > [PHILIPS once a day] small mesentery giant lymph node hyperplasia

    [PHILIPS once a day] small mesentery giant lymph node hyperplasia

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Brief history profile

    The patient, female, 39 years old, had CT for


    Surgery sees

    Intrajejunal nodular mass with a size of 8×6.


    pathology

    Proliferative lymphoid tissue, complete and thickened envelope, atrophic lymphatic follicles scattered in lymphoid tissue (CD20++, CD3+, CD5+, CD43+), epilogenetic center atrophy with vitreous degeneration, mantle cell hyperplasia (bcl2++, CyclinD1-, CD43-), interfollicular angioproliferation, partial tube wall thickening with vitreous degeneration, and see sheet mature plasma cell hyperplasia, powder staining amorphous deposition


    diagnosis

    Giant lymph node hyperplasia


    Diagnostic basis

    Fig.


    Figure 2 is about 1 cm of horizontal enhancement arterial phase scan on the cephalic side of Figure 1, the lesion is significantly strengthened, the lower enhancement area is visible in the center, and the hemosupply lesion of the superior mesenteric artery branch can be seen (arrow number);

    Figure 3 shows the portal vein phase of the enhanced scan at the same level as Figure 2

    Figure 4 shows the same level as Figure 2 at the enhancement scan venous phase, the degree of lesion intensification decreases rapidly;

    Figure 5 Enhanced scanning portal vein stage thin layer scan by lesion long-diameter multiplane recombination (MPR), showing that the lesion is oblong, and the long axis is roughly the same as that of the mesenteric blood vessels (arrow number).


    Comments

    Massive lymph node hyperplasia, also known as Castleman's disease, the cause is unknown; The pathology is divided into type 2, which is common in clinical practice as a transparent vascular type, and a rare plasma cell type


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.